A new look at mechanism-based Alzheimer's Disease biomarkers in blood

对血液中基于机制的阿尔茨海默病生物标志物的新认识

• 批准号: 9763401
• 负责人: DENNIS J SELKOE
• 金额: $ 22.38万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-15 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9763401
• 关键词: Address; Adult; Age; Alzheimer' s Disease; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-Protein; Antibodies; Antigen-Antibody Complex; Antigens; Autoantibodies; Autopsy; Binding; Binding Proteins; Biological Assay; Biological Markers; Blood; Blood Tests; Brain imaging; Caring; Cerebrospinal Fluid; Clinical; Clinical Chemistry; Cognitive; Complex; Conflict (Psychology); Cross-Sectional Studies; Data; Detection; Diagnosis; Diagnostic; Discrimination; Disease; Disease Progression; Down Syndrome; Early Diagnosis; Early intervention trials; Etiology; Genetic; Half-Life; Heterogeneity; Histopathology; Human; Immobilization; Immunoassay; Impaired cognition; Individual; Length; Link; Longitudinal Studies; Measurement; Measures; Medical Genetics; Microtubules; Molecular; Monitor; N-terminal; Nature; Pathogenesis; Pathologic; Pathologic Processes; Patients; Pattern; Phase; Pilot Projects; Plasma; Positron-Emission Tomography; Preparation; Presenile Alzheimer Dementia; Proteins; Reproducibility; Resistance; Risk; Sampling; Sampling Studies; Secondary Prevention; Specificity; Specimen; Statistical Data Interpretation; Study Subject; Symptoms; Testing; Therapeutic; Time; Universities; aged; analytical method; antigen binding; base; blood-based biomarker; cohort; demented; disorder control; exosome; experimental study; extracellular; human disease; human old age (65+); insight; mindfulness; neuropathology; novel; pre-clinical; prospective; protein B; prototype; tau Proteins

A blood test to identify cognitively unimpaired individuals at risk for Alzheimer's disease (AD) and the emergence of AD in Down syndrome (DS) is desperately needed. Here, we propose experiments to address this unmet need. Specifically, we will measure (in plasma) levels of proteins (tau and Aβ) implicated in the etiology of AD, and naturally occurring autoantibodies (NAbs) against these proteins. In blood tau and Aβ are present in distinct pools, e.g. free floating, bound to other proteins, and inside exosomes. Numerous prior studies have measured Aβ in plasma, but few took account of the distinct pools and many were confounded by imperfect assays and/or patient specimens. Only a handful of studies have looked at tau in blood, none accounted for the molecular heterogeneity of tau or its occurrence in different pools. In contrast, we will be careful to use assays capable of detecting distinct forms of tau and to assess the contributions of different pools and how they may change with disease. Since tau is present in blood at very low levels and measurement of Aβ in plasma requires dilution to overcome matrix effects, we will use state-of-the-art in-house ultra-sensitive assays developed using the Simoa (tau) and Erenna (Aβ) platforms. NAbs-bound tau and Aβ will be liberated from antigen-antibody complexes and then measured, and free NAbs will be detected by quantifying binding to plate-immobilized antigen. Great care will be taken to include internal standards so as to monitor the sensitivity and reproducibility of our assays. Most prior studies evaluated analytes at only a single time point and there have been few longitudinal studies. Considering the long duration of both the pre-clinical and clinical phases of AD, and how distinct forms of tau, Aβ and NAbs may change during these protracted periods, it is not surprising that cross-sectional studies have, thus far, yielded conflicting and variable results. Mindful of these pitfalls, we propose for the first time to measure anti-tau and anti-Aβ NAbs and their cognate antigens in the same plasma samples using specimens from carefully characterized study subjects. To gain insight on how tau, Aβ and NAbs change throughout the course of the disease, we will apply our well- characterized assays to plasma samples from 3 distinct cohorts. These will include samples that have been collected prospectively before and just after clinical onset from individuals of whom a detailed set of clinical, genetic, and histopathology data exist, and plasma from 0-65 years old DS subjects. DS is the most common genetic cause of early-onset AD and most DS adults become demented before the age of 60. Thus, studying samples from different-aged DS subjects provides a window on different stages of AD, and should also identify the optimal therapeutic interval to treat AD in DS. Combining this systematic approach with careful statistical analysis we expect to identify one, or possibly a selection of analytes, that can: (i) accurately detect subjects at risk of developing AD, and (ii) determine an appropriate age range in which to treat AD in DS.

一项血液测试可以识别认知能力未受损的人患阿尔茨海默病（AD）的风险